| P50 | author | Herbert Spapen | Q82143470 |
| | Frédérique Jacobs | Q114294125 |
| | Françoise Van Bambeke | Q37828419 |
| | Paul M Tulkens | Q40634916 |
| P2093 | author name string | Pierre-François Laterre | |
| | Maya Hites | |
| | Fabio S Taccone | |
| | Isabelle K Delattre | |
| | Pierre E Wallemacq | |
| | Thierry Dugernier | |
| P2860 | cites work | Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration | Q24620193 |
| | Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients | Q33508985 |
| | Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa | Q33676227 |
| | Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? | Q33751132 |
| | Prospective monitoring of cefepime in intensive care unit adult patients | Q33919165 |
| | Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure | Q33938048 |
| | Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients | Q33983364 |
| | Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock | Q34153182 |
| | Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa | Q34228382 |
| | Animal model pharmacokinetics and pharmacodynamics: a critical review | Q34615868 |
| | How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? | Q34894900 |
| | Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? | Q35124710 |
| | Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units | Q35607715 |
| | Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid | Q35623055 |
| | Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections | Q35759054 |
| | Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model | Q35820123 |
| | Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams | Q35908084 |
| | Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements | Q35960694 |
| | Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies | Q35960873 |
| | Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis | Q36053937 |
| | Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations? | Q36158212 |
| | Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections | Q36171570 |
| | Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability | Q36263480 |
| | Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? | Q36517624 |
| | Pharmacodynamic optimization of beta-lactams in the patient care setting | Q37169843 |
| | Antibiotic resistance--what's dosing got to do with it? | Q37205795 |
| | Cefepime versus cefpirome: the importance of creatinine clearance | Q44590534 |
| | Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion | Q44636916 |
| | Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. | Q45022843 |
| | Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia | Q45091004 |
| | Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. | Q45228805 |
| | Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia | Q46603539 |
| | A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit | Q46665600 |
| | Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis. | Q46667730 |
| | Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections | Q46723444 |
| | Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient | Q46878735 |
| | A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam | Q47960490 |
| | Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. | Q50260879 |
| | Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. | Q51796852 |
| | Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. | Q54452950 |
| | Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. | Q54456655 |
| | Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. | Q54766719 |
| | DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients? | Q57237700 |
| | Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? | Q37335840 |
| | Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission. | Q37392874 |
| | Pharmacokinetic issues for antibiotics in the critically ill patient | Q37399820 |
| | Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? | Q37516599 |
| | Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia | Q37643682 |
| | Protein binding: do we ever learn? | Q37871252 |
| | β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review | Q38004063 |
| | Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. | Q38741453 |
| | β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia | Q39519654 |
| | Pharmacodynamics of cefepime in patients with Gram-negative infections | Q39614211 |
| | Optimization of meropenem dosage in the critically ill population based on renal function | Q39961839 |
| | Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial | Q40156961 |
| | Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria | Q40346786 |
| | Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins | Q40431109 |
| | Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patien | Q40470332 |
| | The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents | Q40517235 |
| | Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia | Q40519156 |
| | A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients | Q40600997 |
| | Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy | Q40699490 |
| | Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients | Q40727311 |
| | Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock | Q40810754 |
| | Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy | Q41148311 |
| | Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis | Q41337771 |
| | Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial in | Q41349399 |
| | Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia | Q41493923 |
| | Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations. | Q41681159 |
| | Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy? | Q41692446 |
| | Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 |
| | Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study | Q41741255 |
| | Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations | Q42006135 |
| | Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients | Q42217637 |
| | An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units | Q42232248 |
| | Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients | Q42254710 |
| | Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy | Q42646756 |
| | In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy | Q42868287 |
| | Population pharmacokinetics of meropenem in burn patients | Q42917443 |
| | Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept | Q42946682 |
| | Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia | Q43153489 |
| | First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis | Q43216988 |
| | Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin | Q43440516 |
| | Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. | Q43539075 |
| | Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections | Q43829748 |
| | Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients | Q43829751 |
| | Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion | Q43884648 |
| | Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients | Q43890466 |
| | Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. | Q43962798 |
| | Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course. | Q44130127 |
| | Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration | Q44459246 |
| P433 | issue | 7 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| | pharmacodynamics | Q725307 |
| P304 | page(s) | 677-688 | |
| P577 | publication date | 2017-06-02 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? | |
| P478 | volume | 15 | |